Tagrisso is AstraZeneca’s top-selling cancer drug, and in the second quarter of 2024, it generated around $1.6 billion in sales. The approval follows the FDA’s Priority Review based on results ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca noted that Tagrisso is approved for patients with EGFR mutations in the 1st-line metastatic setting as a monotherapy and in combination with chemotherapy, ...

AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC ...

AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...

WILMINGTON, Del. -- (BUSINESS WIRE)-- AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...